Chengdu, China – In a move that underscores its commitment to innovation and excellence, Qilian International Holding Group Ltd (the "Company") has announced a series of strategic leadership and board appointments. These changes are set to inject new energy into the company's drive for breakthrough innovation in the pharmaceutical sector.
Chairman's Vision: Chairman Zhanchang Xin is set to lead the company into a future brightened by the core values of courage, excellence, equity, and joy. His leadership is expected to inspire continued dedication to these principles, propelling the company forward.
CFO's Dedication to Growth: Yaxuan Zhai, MSF, the CFO, is recognized for his steadfast focus on cost-effectiveness and growth, ensuring operations are in perfect harmony with the company's pursuit of excellence and sustainability.
CEO's Global Impact: CEO Chen Xin is at the helm of the company's global pharmaceutical endeavors, guiding the organization to new heights in safeguarding human and animal health and fostering a beneficial circular economy.
Board Reshuffling for Enhanced Diversity: The company has seen a reshuffling of its board with the resignation of Ms. Song Gao and Mr. Dingqian Liu, both due to personal reasons and unrelated to any company disagreements. This has paved the way for a refreshed board composition that now better represents gender diversity, moving from a 4:1 male-to-female ratio to a more balanced 2:2.
New Independent Director Appointment: Ms. Waihua Xu, with her extensive experience in marketing and public relations, has been appointed as an independent director. Her appointment is effective as of May 31, 2024, and she will chair the nominating and corporate governance committee, as well as serve on the compensation and audit committees.
Ms. Xu's Background: Aged 31, Ms. Xu has demonstrated leadership in social media and community management at Shenzhen Geruidi Technology, Ltd., and has a strong background in new media operations and marketing strategy development. Her educational credentials include a master’s degree in Leadership from Trinity Western University and a bachelor’s degree in English from Hunan Institute of Engineering.
New Director Appointment: Ms. Furong Cao, with her rich experience in business management across various industries, has also been appointed to the board. Her appointment is effective immediately, further strengthening the board's expertise in operations and investment strategies.
Ms. Cao's Background: At 54, Ms. Cao brings a wealth of business management experience to the board, with a background that includes roles in financial project planning and investment risk assessment. She holds a bachelor’s degree in Medical Profession from Shanghai Second Medical College.
Positive Outlook: The company is optimistic about the positive impact these changes will have on its development. The new appointments are expected to contribute fresh perspectives and strategic insights, enhancing the board's ability to innovate and lead in the dynamic pharmaceutical landscape.
About Qilian International Holding Group Ltd: Based in Chengdu, China, Qilian International Holding Group Ltd is a prominent player in the global pharmaceutical industry. The company is dedicated to advancing health and well-being through innovative research and development. With a renewed focus on board diversity, the company is poised to embrace new opportunities for sustainable growth.
Qilian International Holding Group Ltd has announced major leadership and board changes, including the appointment of new CEO and CFO, along with the addition of two new directors. These strategic updates are expected to foster innovation and propel the company’s growth in the pharmaceutical sector.
